SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wodarz A, Nusse R 1998 Mechanism of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 5989.
  • 2
    Uusitalo M, Heikkila M, Vainio S 1999 Molecular genetic studies of Wnt signaling in the mouse. Exp Cell Res 253: 336348.
  • 3
    Westendorf JJ, Kahler RA, Schroeder TM 2004 Wnt signaling in osteoblasts and bone diseases. Gene 341: 1939.
  • 4
    Yang-Snyder J, Miller JR, Brown JD, Lai C, Moon RT 1996 A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol 6: 13021306.
  • 5
    Slusarski DC, Corces VG, Moon RT 1997 Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 390: 410413.
  • 6
    He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H 1997 A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275: 16521654.
  • 7
    Wang YK, Samos CH, Peoples R, Perez-Jurado LA, Nusse R, Francke U 1997 A novel human homologue of the Drosophila frizzled wnt receptor gene binds wingless protein and is in the Williams syndrome deletion at 17q11.23. Hum Mol Genet 6: 465472.
  • 8
    Hsieh JC, Rattner A, Smallwood PM, Nathans J 1999 Biochemical characterization of Wnt-Frizzled interactions using soluble, biologically active vertebrate Wnt protein. Proc Natl Acad Sci USA 96: 35463551.
  • 9
    Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC 2000 An LDL-receptor-related protein mediates Wnt signaling in mice. Nature 407: 535538.
  • 10
    Mao J, Wang J, Liu B, Pan W, Farr GH III, Flynn C, Yuan H, Takada S, Kimelman D, Li L, Wu D 2001 Low-density lipoprotein receptor-related protein-5 binds to axin and regulates the canonical Wnt signaling pathway. Mol Cell 7: 801809.
  • 11
    Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C 2001 LDL-receptor- related protein 6 is a receptor for Dickkopf proteins. Nature 411: 321325.
  • 12
    Frame S, Cohen P 2001 GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 116.
  • 13
    Woodgett JR 1990 Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 24312438.
  • 14
    Woodgett JR 1991 cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 200: 564577.
  • 15
    Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccolo B, Paepe AD, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinman B, Sullivan B, Superti-Furga A, Swoboda W, Boogaard MJV, Hul WV, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513523.
  • 16
    Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 15131520.
  • 17
    Little RD, Carulli JP, Del Mestro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Eerdewegh PV, Recker RR, Johnson ML 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone- mass trait. Am J Hum Genet 70: 1119.
  • 18
    Wesenbeeck LV, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, Varnejoul MCD, Bollerslev J, Hul WV 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72: 763771.
  • 19
    Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PVN, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F 2003 High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18: 960974.
  • 20
    Kato M, Patel MS, Levasseur R, Lobov I, Chang BHJ, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L 2002 Cbfa 1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in LRP5, a Wnt coreceptor. J Cell Biol 157: 303314.
  • 21
    Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO 2004 Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19: 20332040.
    Direct Link:
  • 22
    Bain G, Muller T, Wang X, Papkoff J 2003 Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 301: 8491.
  • 23
    Rawadi GS, Vayssiere B, Dunn F, Baron R, Roman-Roman S 2000 BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18: 18421853.
  • 24
    Mbalaviele G, Sheikh S, Stains JP, Salazar VS, Cheng SL, Chen D, Civitelli R 2005 β-Catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 94: 403418.
  • 25
    Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G 2005 Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751764.
  • 26
    Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, Mendel D, Misener E, Briere D, O'Toole JC, Porter WJ, Queener S, Reel JK, Owens RA, Brier RA, Eessalu TE, Wagner JR, Campbell RM, Vaughn R 2004 Substituted 3-imidazo[1,2-α] pyridine-3-yl-4-91,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J Med Chem 47: 39343937.
  • 27
    Onyia JE, Bidwell J, Herring J, Hullman J, Hock JM 1995 In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17: 479484.
  • 28
    McClelland P, Onyia JE, Miles R, Tu Y, Liang J, Harvey AK, Chandrasekhar S, Hock J, Bidwell JP 1998 Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in long bone. J Cell Biochem 70: 391401.
  • 29
    Winkler DG, Sutherland MSK, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA 2005 Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280: 24982502.
  • 30
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2: 595610.
  • 31
    Ma YF, Li XJ, Jee WSS, McOsker J, Liang XG, Setterberg R 1995 Effects of prostaglandin F on the skeleton of adult osteopenic ovariectomized rats. Bone 17: 549554.
  • 32
    Sato M, Rippy MK, Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen Effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 10: 905912.
  • 33
    Borchert KM, Galvin RJS, Frolik CA, Hale LV, Halladay DL, Gonyier RJ, Trask OJ, Nickischer DR, Houck KA 2005 High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Technol Drug Dev 3: 133141.
  • 34
    Coghlan MP, Culbert AA, Cross DAE, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Cox LR, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC 2000 Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793803.
  • 35
    Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L 2001 Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal Tau phosphorylation in alzheimer's disease. J Biol Chem 276: 251260.
  • 36
    Lacroix CP, Ai M, Chiusaroli R, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Warman M, Baron R, Rawadi G 2004 Inhibition of GSK-3β by lithium chloride reverses the osteoporotic phenotype displayed by Lrp5 deficient mice and increases bone density in intact C57B16 and in osteopenic SAMP6 mice. J Bone Miner Res 19: S1; S16.
  • 37
    Jackson A, Vayssiere B, Garcia T, Newell W, Baron R, Roman-Roman S, Rawadi G 2005 Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36: 585598.
  • 38
    Wang YH, Liu Y, Buhl K, Rowe DW 2005 Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP. J Bone Miner Res 20: 514.
  • 39
    Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 280: 2116221168.
  • 40
    Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L 1993 Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14: 865869.
  • 41
    Bollerslev J, Steiniche T, Melsen F, Mosekilde L 1989 Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: A study of two radiological types. Bone 10: 1924.
  • 42
    Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K, Dipseland O 1998 Biochemical markers of bone metabolism in benign human osteopetrosis: A study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol 138: 2935.
  • 43
    Bollerslev J, Ueland T, Odgren PR 2003 Serum levels of TGF-beta and fibronectin in autosomal dominant osteopetrosis in relation to underlying mutations and well described murine counterparts. Crit Rev Eukaryot Gene Expr 13: 163171.
  • 44
    Cohen P, Frame S 2001 The renaissance of GSK3. Nature Rev 2: 769776.